Integrated Chinese and Western Medicine Specialized Disease Cohort for Colorectal Cancer
Integrative Chinese and Western Medicine for Colorectal Cancer: A Nationwide Prospective Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Hai bo Cheng, Professor
- Phone Number: 025-85811001
- Email: hbcheng@njucm.edu.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
CRC patients:
- The patient is over 18 years old;
- The patient meets the diagnostic criteria for colorectal cancer;
- The patient has not received anti-tumor treatment such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunity in the past;
- The patient voluntarily participated in this study and signed an informed consent form.
Colorectal adenoma patients
- The patient is over 18 years old;
- The patient meets the diagnostic criteria for colorectal adenoma;
- The patient voluntarily participated in this study and signed an informed consent form.
Exclusion Criteria:
CRC patients:
- Combined with other malignant tumors;
- The patient has severe cognitive impairment, dementia, and various mental disorders.
Colorectal adenoma patients:
- The patient had a history of malignancy;
- The patient has severe cognitive impairment, dementia, and various mental disorders.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Rectal cancer cohort
20,000 patients with rectal cancer will be included in this cohort and followed for five years.
|
|
Colon cancer cohort
20,000 patients with colon cancer will be included in this cohort and followed for five years.
|
|
Colorectal adenoma cohort
10,000 patients with colorectal adenomas will be enrolled in this cohort and followed for five years.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival of patients with CRC
Time Frame: 5 years
|
Patients were recorded from the time they entered the study until their final death.
|
5 years
|
|
The detection rate of Colorectal Adenomatous Polyp.
Time Frame: 5 years
|
In the follow-up plan, record the proportion of patients diagnosed with colorectal adenoma after colonoscopy examination.
|
5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life of CRC patients
Time Frame: 5 years
|
The quality of life will be evaluated using the KPS score.
The higher the KPS score, the better the patient's health condition.
|
5 years
|
|
Recurrence rate of CRC patients
Time Frame: 5 years
|
Record the number of patients with recurrence at each time point.
|
5 years
|
|
Metastasis rate of CRC patients
Time Frame: 5 years
|
Record the number of patients with metastasis at each time point.
|
5 years
|
|
Disease-free survival (DFS) of CRC patients
Time Frame: 5 years
|
The evaluation criteria for DFS are as follows: after radical treatment, the patient has reached a disease-free state or complete remission, and after this, the time span until the first assessment of tumor recurrence or metastasis or death without recurrence or metastasis, the patient is in a tumor free state at this stage.
|
5 years
|
|
Progression-free survival (PFS) of CRC patients
Time Frame: 5 years
|
The evaluation criteria for PFS are as follows: the time span from the start of tumor treatment upon patient enrollment to the first assessment of disease progression or death without progression, during which the tumor has basically not progressed.
|
5 years
|
|
The canceration rate of Colorectal Adenomatous Polyp.
Time Frame: 5 years
|
In the follow-up plan, record the proportion of patients diagnosed with colorectal cancer after colonoscopy examination.
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Hai bo Cheng, Professor, Nanjing University of Chinese Medicine
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenoma
Other Study ID Numbers
Other Study ID Numbers
- ZLXTCXZX-2023001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.